Join today and have your say! It’s FREE!

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

ExoTherapy offers hope for treating acute spinal cord injuries

Suffering from traumatic injuries can leave a person with long-term damages and/or side effects that are hard to navigate long after the initial incident has passed. Our next company is a publicly traded bio-pharmaceutical company, working on the development of its ...

NervGen Pharma: A “Blockbuster Drug” in the Making?

It has the potential to be one of the most disruptive pharmaceutical drug therapies of the modern era, especially for treating Alzheimer’s disease. And that gives it considerable “blockbuster drug” potential – a tantalising opportunity tha...

Cracking the Code to Society’s Most Feared Disease

Even more so than cancer, it’s the one disease that we all fear the most. The thought of falling prey to Alzheimer’s disease and to the inevitable desecration of our mind is something that makes even the bravest among us shudder. ...

NurExone Biologic announces important test results

By Brad Sorensen, CFA, Zacks Research. NurExone Biologic (TSXV:NRX; OTCQB:NRXBF) is developing a product known as ExoPTEN that is designed to treat patients with acute spinal cord injuries, while also conducting preclinical tests for other conditions that ExoPTEN m...

‘Power to the People’ and mining

The 1960s and 70s were decades of incredible social upheaval. Fed up with wars, governments out of touch with their ideals, authority figures who didn’t get them, the “flower children” of the '60s took to the streets to demand equal ri...

NervGen: Are amazing human trial results leaking out?

“We are very excited! We are very, very excited!” So says Dr. Monica Perez, who is running the first human trial for a potential new wonder drug being developed by a tiny but well-financed life sciences start-up, NervGen Pharma Corp. ...

Crystal Lake Mining Site Visit

I am not a proponent of global warming, pollution and receding ice fields. But reality is that these things are unfortunately transpiring and I am hoping that humanity becomes more socially responsible and that these catastrophes come to a stop or at least slow down. There a...

I do not trust the markets currently but Cole Evans is a different story.

These are perilous times with both a fast spreading virus and socioeconomic challenges. This was the theme of my talk at the newsletter writers presentation at PDAC and during my media interviews. Markets have a propensity to overshoot and over correct. Unfortunately I was r...

Gratomic: Eco-conscious and On The Move

Graphite has been around for what it seems to be forever. I’m sure we all remember using a form of this naturally-occurring crystalline carbon as kids in our yellow No. 2 pencils. The popularity of this highly versatile mineral with other uses incl...

The Golden Question

Call it a dream, stupidity or mere eventuality but a year or two ago when gold was hovering between US$1150/ounce and US$1200/ounce, I spoke about my prediction that gold may hit $2000 US/ounce within a few short years. At this year’s PDAC conference, during...
1 2 3 4 5 6 7 8 9 10 ...